Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Apr 26:2022:2677312.
doi: 10.1155/2022/2677312. eCollection 2022.

Emerging Roles of FTO in Neuropsychiatric Disorders

Rui Chang  1 , Zeyi Huang  1 , Size Zhao  1 , Ju Zou  1 , Yukun Li  1 , Sijie Tan  1
Affiliations
Review

Emerging Roles of FTO in Neuropsychiatric Disorders

Rui Chang et al. Biomed Res Int. .

Abstract

FTO (fat mass and obesity associated) is a recently discovered gene related to obesity and expressed in various tissues of the human body, especially with high expression in the brain. Earlier studies have found that FTO is involved in several biological processes, including brain development and function. In particular, recent studies have found that FTO is a demethylase of N6-methyladenosine (m6A) and it can affect neurological function through the m6A modification of mRNA. At present, a number of studies have shown that FTO is associated with many neuropsychiatric disorders. This paper reviews the discovery, structure, function, and tissue expression of FTO followed by discussing the relationship between FTO and neuropsychiatric diseases. In addition, the potential roles of FTO gene in drug addiction, major depression (MDD), and schizophrenia (SCZ) through regulating m6A modification of dopamine related genes were also highlighted.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

References

    1. Rotenstein L. S., Ramos M. A., Torre M., et al. Prevalence of depression, depressive symptoms, and suicidal ideation among medical students: a systematic review and meta-analysis. JAMA . 2016;316(21):2214–2236. doi: 10.1001/jama.2016.17324. - DOI - PMC - PubMed
    1. Zuckerman H., Pan Z., Park C., et al. Recognition and treatment of cognitive dysfunction in major depressive disorder. Frontiers in Psychiatry . 2018;9:p. 655. doi: 10.3389/fpsyt.2018.00655. - DOI - PMC - PubMed
    1. Chakos M., Lieberman J., Hoffman E., Bradford D., Sheitman B. Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials. The American Journal of Psychiatry . 2001;158(4):518–526. doi: 10.1176/appi.ajp.158.4.518. - DOI - PubMed
    1. Leucht S., Corves C., Arbter D., Engel R. R., Li C., Davis J. M. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet . 2009;373(9657):31–41. doi: 10.1016/S0140-6736(08)61764-X. - DOI - PubMed
    1. Leucht S., Cipriani A., Spineli L., et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet . 2013;382(9896):951–962. doi: 10.1016/S0140-6736(13)60733-3. - DOI - PubMed

MeSH terms